These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 19008789

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Drug essentials. An alkylating agent for CLL and NHL.
    Wilkes GM.
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):55-6. PubMed ID: 19856600
    [No Abstract] [Full Text] [Related]

  • 5. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D, Tulpule A.
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
    Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E.
    Expert Rev Hematol; 2010 Apr; 3(2):131-48. PubMed ID: 21083456
    [Abstract] [Full Text] [Related]

  • 12. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Severe cutaneous interface drug eruption associated with bendamustine.
    Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW.
    Dermatol Online J; 2010 Jul 15; 16(7):1. PubMed ID: 20673529
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bendamustine: rebirth of an old drug.
    Cheson BD, Rummel MJ.
    J Clin Oncol; 2009 Mar 20; 27(9):1492-501. PubMed ID: 19224851
    [Abstract] [Full Text] [Related]

  • 19. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M.
    Clin Lymphoma Myeloma Leuk; 2010 Feb 20; 10(1):21-7. PubMed ID: 20223726
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.